Dipexium Pharmaceuticals Llc (DPRX) 9.49 $DPRX
Dipexium Pharmaceuticals Initiates Second of Two Pivotal Phase 3 Clinical Trials of Locilex® in Patients with Mild Infections of Diabetic Foot Ulcers
PR Newswire - Mon Jul 21, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced it has initiated patient enrollment in the second of two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI. According to medical literature, approximately 47% of all patients with diabetic foot infections first present at the mild stage. Currently, there are no antibiotics, systemic or topical, which are FDA approved specifically to treat patients with Mild DFI. The U.S. Food and Drug Administration has agreed to a Special Protocol Assessment (SPA) with Dipexium for Locilex®'s pivotal Phase 3 clinical trial program in Mild DFI.
Dipexium Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Locilex® in Patients with Mild Infections of Diabetic Foot Ulcers
PR Newswire - Thu Jul 17, 7:01AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced it has initiated patient enrollment in the first of two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI. According to medical literature, approximately 47% of all patients with diabetic foot infections first present at the mild stage. Currently, there are no antibiotics, systemic or topical, which are FDA approved specifically to treat patients with Mild DFI. The U.S. Food and Drug Administration has agreed to a Special Protocol Assessment (SPA) with Dipexium for Locilex®'s pivotal Phase 3 clinical trial program in Mild DFI.
Dipexium Pharmaceuticals Announces Successful Completion of Phase 1 Skin Irritation Trial of Locilex®
PR Newswire - Thu Jul 17, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced successful completion and initial results of DPX-110, a Phase 1 skin irritation clinical trial of Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum topical antibiotic peptide. Dipexium conducted DPX-110 and the company is conducting DPX-120, a Phase 1 skin sensitization clinical trial, in parallel with two required pivotal Phase 3 clinical trials for Locilex®. The Company's pivotal Phase 3 clinical program is subject to a Special Protocol Assessment (SPA) agreement with FDA.
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Jul 16, 9:00AM CDT
What:
Dipexium Pharmaceuticals, Inc. on Preliminary List of Additions to Russell Microcap® Index
PR Newswire - Mon Jun 23, 9:38AM CDT
Dipexium Pharmaceuticals, Inc. (NasdaqCM: DPRX), today announced it was included in the preliminary list of additions to the Russell Microcap® Index according to information posted by Russell Investments on June 13, 2014. The final 2014 reconstitution of the Russell Indexes will take place after the market closes on June 27, 2014 and final membership lists will be posted on June 30, 2014, with trading in the reconstituted indexes commencing that same day.
Dipexium Pharmaceuticals Closes Initial Public Offering
PR Newswire - Tue Mar 18, 10:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ
PRX), a late stage biopharmaceutical company developing Locilex(TM) (pexiganan acetate cream 1%), a proposed treatment for mild infections of diabetic foot ulcers, today announced the closing of its initial public offering of 3,162,500 shares of its common stock at a public offering price of $12.00 per share.
Dipexium Pharmaceuticals Prices Initial Public Offering of Common Stock
PR Newswire - Thu Mar 13, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ PRX), a late stage biopharmaceutical company developing Locilex(TM) (pexiganan acetate cream 1%), a proposed treatment for mild infections of diabetic foot ulcers, today announced the pricing of its initial public offering of 2,750,000 shares of its common stock at a public offering price of $12.00 per share. All shares of common stock are being offered by the company. In addition, Dipexium has granted the underwriters a 30-day option to purchase up to an additional 412,500 shares of common stock at the same price to cover over-allotments, if any.
Dipexium Pharmaceuticals Initiates Second of Two Pivotal Phase 3 Clinical Trials of Locilex® in Patients with Mild Infections of Diabetic Foot Ulcers
PR Newswire - Mon Jul 21, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced it has initiated patient enrollment in the second of two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI. According to medical literature, approximately 47% of all patients with diabetic foot infections first present at the mild stage. Currently, there are no antibiotics, systemic or topical, which are FDA approved specifically to treat patients with Mild DFI. The U.S. Food and Drug Administration has agreed to a Special Protocol Assessment (SPA) with Dipexium for Locilex®'s pivotal Phase 3 clinical trial program in Mild DFI.
Dipexium Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Locilex® in Patients with Mild Infections of Diabetic Foot Ulcers
PR Newswire - Thu Jul 17, 7:01AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced it has initiated patient enrollment in the first of two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum, topical antibiotic peptide, for the treatment of patients with mild infections of diabetic foot ulcers, or Mild DFI. According to medical literature, approximately 47% of all patients with diabetic foot infections first present at the mild stage. Currently, there are no antibiotics, systemic or topical, which are FDA approved specifically to treat patients with Mild DFI. The U.S. Food and Drug Administration has agreed to a Special Protocol Assessment (SPA) with Dipexium for Locilex®'s pivotal Phase 3 clinical trial program in Mild DFI.
Dipexium Pharmaceuticals Announces Successful Completion of Phase 1 Skin Irritation Trial of Locilex®
PR Newswire - Thu Jul 17, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) today announced successful completion and initial results of DPX-110, a Phase 1 skin irritation clinical trial of Locilex® (pexiganan cream 0.8%), the company's novel, broad-spectrum topical antibiotic peptide. Dipexium conducted DPX-110 and the company is conducting DPX-120, a Phase 1 skin sensitization clinical trial, in parallel with two required pivotal Phase 3 clinical trials for Locilex®. The Company's pivotal Phase 3 clinical program is subject to a Special Protocol Assessment (SPA) agreement with FDA.
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Jul 16, 9:00AM CDT
What:
Dipexium Pharmaceuticals, Inc. on Preliminary List of Additions to Russell Microcap® Index
PR Newswire - Mon Jun 23, 9:38AM CDT
Dipexium Pharmaceuticals, Inc. (NasdaqCM: DPRX), today announced it was included in the preliminary list of additions to the Russell Microcap® Index according to information posted by Russell Investments on June 13, 2014. The final 2014 reconstitution of the Russell Indexes will take place after the market closes on June 27, 2014 and final membership lists will be posted on June 30, 2014, with trading in the reconstituted indexes commencing that same day.
Dipexium Pharmaceuticals Closes Initial Public Offering
PR Newswire - Tue Mar 18, 10:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ
PRX), a late stage biopharmaceutical company developing Locilex(TM) (pexiganan acetate cream 1%), a proposed treatment for mild infections of diabetic foot ulcers, today announced the closing of its initial public offering of 3,162,500 shares of its common stock at a public offering price of $12.00 per share. Dipexium Pharmaceuticals Prices Initial Public Offering of Common Stock
PR Newswire - Thu Mar 13, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ
PRX), a late stage biopharmaceutical company developing Locilex(TM) (pexiganan acetate cream 1%), a proposed treatment for mild infections of diabetic foot ulcers, today announced the pricing of its initial public offering of 2,750,000 shares of its common stock at a public offering price of $12.00 per share. All shares of common stock are being offered by the company. In addition, Dipexium has granted the underwriters a 30-day option to purchase up to an additional 412,500 shares of common stock at the same price to cover over-allotments, if any. 
